MedTrace Logo

Study to Evaluate the Safety and Efficacy of Switching Calcineurin Inhibitor to Everolimus After Kidney Transplantation in Adults

NCT01455649 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2011-10-20

No results posted yet for this study

Summary

The purpose of this study is to demonstrate the efficacy and safety in the use of everolimus, with its onset after 3 months of treatment with calcineurin inhibitor.

Conditions

  • Kidney Transplant
  • Immunosuppression

Interventions

DRUG

Everolimus

Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).

DRUG

calcineurin inhibitor

Group will maintain their initial immunosuppression therapy with calcineurin inhibitor

Sponsors & Collaborators

  • Deise de Boni Monteiro de Carvalho

    lead OTHER

Principal Investigators

  • Francisco G Miloski, MD · Physician

  • Tereza Matuck, MD · Chief of the Nephrology Department

  • Regina Sousa · Head Nurse of The Nephrology Department

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-11-30
Primary Completion
2013-11-30
Completion
2013-11-30

Countries

  • Brazil

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01455649 on ClinicalTrials.gov